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Abstract
Background: Chemo-resistance to cisplatin-centered cancer therapy is a major obstacle to the effective treatment of human
ovarian cancer. Previous reports indicated that arsenic trioxide (ATO) induces cell apoptosis in both drug-sensitive and -
resistant ovarian cancer cells.
Principal Findings: In this study, we determined the molecular mechanism of ATO-induced apoptosis in ovarian cancer
cells. Our data demonstrated that ATO induced cell apoptosis by decreasing levels of phosphorylated AKT (p-AKT) and
activating caspase-3 and caspase-9. Importantly, BIM played a critical role in ATO-induced apoptosis. The inhibition of BIM
expression prevented AKT dephosphorylation and inhibited caspase-3 activation during cell apoptosis. However,
surprisingly, gene silencing of AKT or FOXO3A had little effect on BIM expression and phosphorylation. Moreover, the
activation of caspase-3 by ATO treatment improved AKT dephosphorylation, not only by cleaving the regulatory A subunit
of protein phosphatase 2A (PP2A), but also by increasing its activation. Furthermore, our data indicated that the c-Jun N-
terminal kinases (JNK) pathway is involved in the regulation of BIM expression.
Conclusions: We demonstrated the roles of BIM in ATO-induced apoptosis and the molecular mechanisms of BIM
expression regulated by ATO during ovarian cancer cell apoptosis. Our findings suggest that BIM plays an important role in
regulating p-AKT by activating caspase-3 and that BIM mediates the level of AKT phosphorylation to determine the
threshold for overcoming cisplatin resistance in ovarian cancer cells.
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Introduction
Ovarian cancer is the most common cause of cancer deaths
from gynecologic tumors [1]. Cisplatin and its analogues are the
key compounds of chemotherapy for human ovarian cancers, but
chemo-resistance is a major obstacle hindering the successful
treatment of ovarian cancer patients [2,3]. Thus, it would be a
major breakthrough in continued preclinical studies to find a new,
low-toxicity, but efficient drug to overcome cisplatin resistance.
ATO, which has been proven to be an effective chemothera-
peutic drug for the treatment of relapsed/refractory acute
promyelocytic leukemia (APL) in the 1990s [4], has been approved
by the FDA (Federal Drug Administration) for treating all-trans
retinoic acid (ATRA)-resistant APL [5]. The remarkable efficacy
of ATO in the treatment of APL has led to the exploration of its
anticancer activity and underlying mechanism in other malignan-
cies. There have been promising studies indicating that ATO not
only possesses inherent single-agent tumoricidal activity against
ovarian-cancer cell lines, but also can trigger apoptosis in cisplatin-
resistant cells [6–10]. However, the precise molecular mechanisms
by which ATO overcomes chemo-resistance and induces apoptosis
in ovarian cancer cells are poorly understood.
Recent evidence suggests that the failure of drug-induced
apoptosis may be an underlying cause of drug resistance. Some
studies have identified a number of key mediators of apoptosis that
are altered in chemo-resistant ovarian cancer cells [10–13]. The
levels of expression and activation of the BCL-2 family proteins
often play important roles in controlling apoptotic responses to
drug treatments, thus modulating the chemo-sensitivity of tumor
cells [14–16]. Overexpression of BCL-2 and BCL-XL genes
contribute to apoptotic inhibition and the development of the
multidrug-resistance of human ovarian cancers. The p53 protein is
also a key regulator of chemo-sensitivity in ovarian cancer cells
and is rapidly upregulated in response to DNA-damaging agents,
such as cisplatin. Moreover, p53 induces apoptosis and regulates
the release of cytochrome c, not only by modulating the
transcription of the BH3-only protein (e.g., PUMA and NOXA),
but also through a transcription-independent mechanism involving
the direct translocation of the p53 protein to the mitochondria
followed by inhibitory interactions with BCL-2 and BCL-XL
[13,17,18].
BIM is also a member of the BH3-only family of pro-apoptotic
proteins and is expressed in a wide variety of tissues [19,20]. As
determined by western blot analysis, most tissues express one
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apoptotic-stress event, BIM translocates to the mitochondria and
initiates the mitochondrial cell death pathway by either directly
activating BAX-like proteins or indirectly binding pro-survival
BCL-2 family members, thereby releasing the BAX-like proteins
[22,23]. The BAX protein has been demonstrated to modulate
apoptosis in ovarian cancer cells [2,13]. However, the effect of
BIM on cisplatin-sensitive and -resistant ovarian cancer cells has
not been thoroughly elucidated.
Recent reports have indicated that AKT is an important
determinant of cisplatin sensitivity in ovarian cancer cells. AKT
promotes cell survival, suppresses apoptosis, and regulates cisplatin
sensitivity in ovarian cancer cells [10–13]. Moreover, AKT, also
known as protein kinase B or Rac [11], is an inactive cytosolic
protein. AKT is recruited to the plasma membrane and activated by
phosphorylation at threonine 308 and serine 473 in response to
growth factors or cytokines [2,10,11,24]. The molecule responsible
for the recruitment of AKT to the cellular membrane, as well as its
activation, is the phosphatidylinositol 3-kinase (PI-3K) [2,11]. Both
PI-3K and AKT are frequently activated and/or overexpressed in
ovarian cancers [2,11,13,25]. Upon activation, AKT phosphorylates
several molecules involved in the regulation of apoptosis, such as the
pro-apoptotic proteins BAD, BIM and caspase-9 and the transcrip-
tion factor FOXO3A. Next, p-AKT blocks the binding of BAD or
BIM to BCL-XL, inhibits caspase-9 protease activity, blocks
FOXO3A function and reduces Fas ligand transcription [19,26–28].
Previous studies have also demonstrated a modulating role of
PI-3K/AKT signaling on BIM expression. The PI-3K inhibitor
LY294002 increases BIM expression in cells concomitant with an
increase in cell death [19]. However, it is proposed that an
important downstream effect of LY294002 is to reduce the
amount of AKT in its active, phosphorylated form [2,19]. The link
between reduced AKT activity and increased BIM expression
levels is FOXO3A, a member of the forkhead family of
transcriptional regulators that can directly increase BIM expres-
sion levels and induce apoptosis in cancer cells when overex-
pressed [19,29,30]. Thus, the upregulation of BIM expression, as
regulated by LY294002, is connected with a loss of AKT activity
and phosphorylation and an increase in the active form of
FOXO3A.
Although the AKT-BIM pathway is important in the chemo-
sensitivity and apoptosis of cancer cells, whether AKT regulates
BIM activity in ovarian cancer cells during ATO treatment
remains unclear. In our report, we showed that the expression
level of BIM was increased and that the phosphorylation of AKT
was decreased during the apoptosis of cisplatin-sensitive and -
resistant cells after ATO treatment. Moreover, the downregulation
of AKT by siRNA could not inhibit BIM expression and
phosphorylation induced by ATO, whereas the knockdown of
BIM prevented AKT dephosphorylation in ovarian cancer cells.
Furthermore, our results demonstrated that ATO-induced AKT
dephosphorylation is dependent on caspase-3-mediated PP2A
activation, which is regulated by BIM expression. These results
suggest that the phosphorylation of AKT is negatively modulated
by BIM and that BIM-mediated AKT phosphorylation is a major
molecular event in mediating ATO-induced apoptosis in chemo-
sensitive and -resistant ovarian cancer cells.
Results
ATO induces apoptosis in cisplatin-sensitive and -
resistant ovarian cancer cells
We first determined the growth-inhibitory effect of cisplatin in
various cisplatin-sensitive (COC1 and A2780) and -resistant
(COC1/CP, A2780/CP and OVCAR-3) human ovarian cell
lines, as described previously [31]. Cell viability was detected by
the MTT assay after 72 hours of treatment. As depicted in
Figure 1A, cisplatin caused a dose-dependent reduction of cell
viability in COC1 and A2780 cells, while COC1/CP, A2780/CP
and OVCAR-3 cells demonstrably exhibited resistance to
cisplatin. To examine cisplatin-induced apoptosis, the cells were
treated with 5 mM cisplatin. Next, apoptosis was confirmed by a
DNA fragmentation ELISA assay at various time points. These
results demonstrated that cisplatin effectively induced apoptosis in
cisplatin-sensitive ovarian cells, but not in cisplatin-resistant cells
(Figure 1B). To investigate the effects of ATO on apoptosis in all
ovarian cancer cells, we treated ovarian cancer cells with ATO
and analyzed the cell apoptosis process by a DNA fragmentation
ELISA assay. Our data suggested that ATO induced cell apoptosis
in all ovarian cancer cells, regardless of their differences in chemo-
sensitivity (Figure 1C). Flow-cytometry analysis with Annexin V
staining further revealed that there was no difference in ATO-
induced apoptosis between cisplatin-sensitive and -resistant cells
(Figure 1D).
To determine whether mitochondria play an important role in
ATO-induced cell apoptosis, the release of cytochrome c was
detected by cell fractionation analysis. The results revealed that
ATO induced the release of cytochrome c in a time-dependent
manner in chemo-sensitive and -resistant cells (Figure 1E, F),
suggesting that ATO initiates apoptotic cell death through
mitochondrial dysfunction.
BIM is important for ATO-induced apoptosis in chemo-
sensitive and -resistant ovarian cancer cells
Mitochondrial dysfunction plays an important role in apoptosis
in ovarian cells. Previous studies reported that changes in the gene
expression of BCL-2-family proteins was involved in ATO-
induced apoptosis [32] and that the BH3-only proteins were
necessary for ATO-induced apoptosis in myeloma cells. However,
it is unclear whether BH3 proteins might function in ovarian
cancer cells following ATO treatment. Therefore, we investigated
the expression of BCL-2-family proteins in cisplatin-sensitive and -
resistant cells after ATO treatment. As depicted in Figure 2A, pro-
apoptotic proteins, such as BAX, PUMA and NOXA, were not
significantly changed in COC1 cells at various time points after
ATO treatment. Anti-apoptotic BCL-2 and BCL-XL proteins also
exhibited no major alterations. However, in contrast to other
proteins, the expression level of BIM was markedly increased after
ATO treatment, providing evidence that BIM was involved in
apoptotic cell death in ovarian cancer cells. Meanwhile, ATO
induced BIM expression equally in COC1/CP cells (Figure 2B).
Similar results were also observed in other cell lines (data not
shown). These results suggest that BIM plays an important role in
ATO-induced apoptosis in ovarian cancer cells.
To confirm the effect of BIM on apoptosis in ovarian cancer
cells, we performed gene-silencing experiments using an shRNA
specific for BIM that targeted all known isoforms of its transcript.
Similar to the result depicted in Figure 2A, the expression level of
BIM was high in the control vector-transfected COC1 and
COC1/CP cells after ATO treatment, while BIM expression levels
in cells transfected with a BIM shRNA were relatively low
(Figure 2C). Moreover, the downregulation of BIM inhibited
caspase-9 and caspase-3 cleavage induced by ATO. Similarly,
ATO induced nuclear fragmentation and condensation in control
vector-transfected A2780 and OVCAR-3 cells, but not in BIM
shRNA-transfected cells (Figure 2D). These results provide further
evidence that BIM expression is necessary for ATO-induced
apoptosis in ovarian cancer cells.
BIM-Mediated AKT Phosphorylation
PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e20586Figure 1. ATO induces apoptosis in cisplatin-sensitive and -resistant human ovarian cells. A. Dose-dependent effects of cisplatin in
ovarian cell lines. Cells were exposed to cisplatin at the indicated concentrations in DMEM or RPMI-1640 with 10% FBS in 96 well plate for 72 h and
cell viability was assessed by MTT assay. Graphs showing results of MTT assay. All data are depicted graphically as the means 6 standard errors of the
means for at least three independent experiments. B. Analysis of cell apoptosis. Cells were treated with cisplatin (5 mM) for different periods of time.
Cell apoptosis was quantitatively detected by a cell death ELISA kit. Graphs showing results of quantitative analyses. All data are depicted graphically
as the means 6 standard errors of the means for at least three independent experiments. *, P,0.05, **, P,0.01. C. Effect of ATO on apoptotic death
in cisplatin-sensitive and -resistant cells. Cells were cultured in the presence or absence of ATO (2 mM) for different periods of time, then cell apoptosis
was measured as described in Materials and Methods. All data are depicted graphically as the means 6 standard errors of the means for at least three
independent experiments. *, P,0.05, **, P,0.01. D. Detection of cell apoptosis with flow cytometry analysis. COC1 and COC1/CP cells were treated
with ATO (2 mM) for 48 h, then stained with Annexin V and examined by flow cytometry. E and F. Analyses of cyt c release. After treatment with ATO
for different periods of time, cells were subjected to subcellular fractionation. The cytosolic or mitochondrial fractions were immunoblotted (30 mgo f
protein/lane) with antibody specific for cyt c. b-Actin and Cox IV were used as a protein loading control. Densitometric analysis of the Western blots
was performed and the amount of cyt c was compared to the protein loading control. For cyto cyt c, relative amount of cyt c from treated cells (72 h)
was set as 1, while relative amount from untreated cells (0 h) was set at 1 for mito cyt c. Data are representative of at least three independent
experiments.
doi:10.1371/journal.pone.0020586.g001
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PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e20586Figure 2. ATO regulated BIM expression is important for cell apoptosis in ovarian cancer cells. A and B. Western blots analysis of the
expression level of BCL-2 family protein. Time-dependent analysis of BCL-2 member’s expression levels in COC1/CP and COC1 cells. Cells were treated
with ATO (2 mM) at indicated time, then lysed in NP40 buffer for detection. b-Actin was used as a protein loading control. Individual protein levels
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Recent studies have indicated that AKT modulates BIM
activation either directly or indirectly [19,33]. Moreover, ATO
induces apoptosis in myeloma cells by decreasing AKT activity
and expression in cells [34]. Based on the above observations, we
speculate that AKT is probably involved in ATO-induced
apoptosis by regulating BIM expression. Accordingly, we first
measured whether AKT is involved in ATO-induced apoptosis in
ovarian cancer cells. As shown in Figure 3A, ATO induced the
downregulation of p-AKT at Ser473 in cisplatin-sensitive COC1
cells in a time-dependent manner, although the expression level of
total AKT protein exhibited no change. Downregulation of p-
AKT induced activation of caspase-9 in sensitive COC1 cells.
Similarly, ATO induced the reduction of p-AKT and the cleavage
of caspase-9 in other ovarian cancer cells, in spite of their
differences in chemo-sensitivity.
We then analyzed the expression levels of upstream PI-3K
signaling proteins,whichmight affectp-AKT levels inovarian cancer
cells. As depicted in Figure 3B, levels of PI-3K pathway proteins,
including p85 (the regulatory subunit of PI-3K), PTEN and PDK1
werenotaltered significantlyafterATOtreatmentforvariousperiods
of time in COC1/CP cells. Recent studies suggested that the
mammalian target of rapamycin 2 (mTORC2) or the Rictor protein
was responsible for the activation of p-AKT at Ser473 [35,36], and
the depletion of subunits of intactmTORC2, such as SIN1, abolished
AKT phosphorylation at Ser473. Moreover, Ser2448 on mTOR was
an AKT phosphorylation site, and phospho-Ser2481 was a marker of
mTORC2 complexes [35,37]. Our data demonstrated that the
protein levels of mTOR complex 2, including phospho-mTOR (at
Ser 2481 and 2448), mTOR, RICTOR and SIN1 were not altered
significantly in A2780 cells after exposure to ATO at various periods
of time (Figure 3C). These results suggest that these proteins have no
effect on the p-AKT level.
To validate if AKT signaling is a major molecular target
responsible for ATO-induced apoptosis, we transfected a consti-
tutively active AKT1 gene into OVCAR-3 and A2780 cells and
examined their response to ATO treatment. As presented in
Figure 3D, OVCAR-3 and A2780 cells transfected with AKT1
exhibited obvious resistance to ATO-induced apoptosis.
Moreover, we used LY294002, a PI-3K inhibitor, to inhibit the
phosphorylation of AKT by upstream signaling molecules and
examined the pro-apoptotic effect of ATO in ovarian cancer cells.
We found that ATO alone eliminated p-AKT and induced apoptosis
while LY294002 alone was not sufficient to induce apoptosis, though
it partially decreased p-AKT. Further experiments proved that the
combination of LY294002 and ATO completely eliminated p-AKT
and enhanced induction of apoptosis in COC1 cells (Figure 3E). Our
data indicates that the effect of combination of LY294002 and ATO
on p-AKT and apoptosis is more significant than that of LY294002
alone, and that the AKT signaling pathway is involved in ATO-
induced apoptosis in ovarian cancer cells.
BIM-regulated AKT phosphorylation in cell apoptosis
AKT mediates BIM activation through two primary pathways:
(1) AKT phosphorylates BIM directly and inhibits BIM activation
[19,33], or (2) AKT phosphorylates FOXO3A, leading to its
cytoplasmic retention by 14-3-3 proteins. Thereby, AKT could
not translocate into the nucleus to induce BIM transcription,
meaning that AKT regulates BIM activation indirectly. On the
basis of these observations, we decided to examine whether AKT
affects BIM activation in ovarian cancer cells. We first downreg-
ulated the expression of AKT1 by siRNA in ATO-treated A2780
and OVCAR-3 cells and found that the downregulation of AKT
increased caspase-3 and PARP cleavage during ATO treatment.
However, AKT downregulation had little effect on BIM
expression, though AKT downregulation increased, to some
extent, ATO-induced nuclear fragmentation and followed cell
apoptosis (Figure 4A). Similar results were also found in ATO-
treated ovarian cancer cells when FOXO3A expression was
downregulated using siRNAs targeting FOXO3A (Figure 4B).
These results suggest that the AKT pathway may not be involved
in regulating BIM expression during ATO-induced apoptosis.
To detect BIM phosphorylation during apoptosis, A2780 and
COC1/CP cells were metabolically labeled with [
32P] orthopho-
sphoric acid and treated with ATO for 48 h, and the
phosphorylation of BIM was analyzed by autoradiography. A
previous report demonstrated that BIM induction and phosphor-
ylation increased during apoptosis [38]. Our studies also have
examined BIM phosphorylation and increased BIM expression
after ATO treatment. Our data further revealed that AKT
downregulation by siRNA or an AKT inhibitor (LY294002) could
not decrease BIM phosphorylation in chemo-sensitive and -
resistant cells after ATO treatment (Figure 4C). These results
indicated that AKT inactivation had little to no effect on BIM
phosphorylation and suggested that AKT could not regulate BIM
activation and that other potential mechanisms regarding the
regulation of BIM activation may exist.
However, our further data indicated that knockdown of BIM
inhibited AKT dephosphorylation and caspase-3 cleavage in
chemo-sensitive and-resistant ovarian cancer cells (Figure 4D).
These results suggest that ATO-induced BIM expression prevents
the phosphorylation of AKT, indicating that BIM regulates AKT
activation during ATO stimulation in ovarian cancer cells.
BIM regulates AKT dephosphorylation by caspase-3
activity
Previous reports indicated that AKT was dephosphorylated at
both Thr308 and Ser473 and inactivated in vitro by the protein
phosphatase 2A (PP2A), which formed a complex with AKT.
AKT was activated in cells upon treatment with the PP2A
inhibitors, such as okadaic acid (OA) [39,40]. Recently, it was
reported that caspase-3 regulated the phosphorylation of AKT
through the cleavage of the regulatory A subunit of PP2A (PP2A/
A), which increased PP2A activity [39]. Our results demonstrated
that BIM is involved in the regulation of caspase-3 and AKT
activation (Figure 4D). Therefore, we propose that BIM may
regulate AKT phosphorylation by caspase-3-mediated PP2A
activation in ovarian cells.
To validate our hypothesis, we first determined whether PP2A
mediated AKT phosphorylation in our study. Pretreatment of the
were measured by densitometric analysis of the Western blots and compared to actin levels. Relative amount of individual protein from treated cells
(72 h) was set as 1. C. Effect of BIM shRNA on cell apoptosis. In the same conditions with A, cells were transfected with BIM or Ctrl shRNA for 48 h,
and then treated with or without ATO for 48 h. Cell lysates were prepared and assayed for BIM, caspase-9 and cleaved caspase-3 by western blot. CF
is referred to cleaved caspase-9. Relative fold means amount of BIM compared to actin and Ctrl condition was regarded as 1. D. Detection the effect
of BIM shRNA on cell death with nuclear staining. Cells were transfected with BIM or Ctrl shRNA for 48 h, and then transfected cells were treated with
ATO for 48 h. Cell death was assessed by measuring cells with condensed and fragmented nuclear by microscopy. Arrows indicate the condensed,
fragmented, brightly stained nuclei, which are the hallmark of apoptosis. All data are representative of three independent experiments.
doi:10.1371/journal.pone.0020586.g002
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PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e20586Figure 3. AKT is necessary for ATO-treated cell apoptosis. A. Detection of AKT phosphorylation, expression and caspase-9 activation. Western
blot analysis of total AKT, p-AKT (Ser
473) levels and caspase-9 cleavage in COC1 cells. Cells were treated with ATO (2 mM) at different time and lysed in
NP40 buffer for detection. CF is referred to cleaved caspase-9. The same detection was employed in COC1/CP, A2780 and OVCAR-3. These cells were
treated for 72 h, then lysed and assayed for individual protein levels by Western blot. b-Actin was used as a protein loading control. p-AKT and AKT
levels were measured by densitometric analysis of the Western blots and compared to actin levels. Relative amount of p-AKT or AKT from untreated
cells was considered as 1. B. Protein levels of the PI-3K signaling pathway in ATO-treated cells. Cells were exposed to drug for different periods of
time. Cell lysates were prepared and assayed for individual protein levels by Western blot. Individual protein levels were measured by densitometric
analysis of the Western blots and compared to actin levels. Relative amount of individual protein from untreated cells (0 h) was set as 1. C. Effects of
ATO on protein levels of mTOR2, including p-mTOR (Ser
2448and
2481), mTOR, RICTOR, SIN1, in A2780 cells. Cells were exposed to drug as described in
B, and then cell lysates were assayed by Western blot. Relative amount of protein levels were set as described in B. Cell lysates were assayed by
western blot. Relative amount of protein levels were set as described in B. D. Protective effect of constitutive AKT on ATO-induced apoptosis in
BIM-Mediated AKT Phosphorylation
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of ATO-induced AKT dephosphorylation in a dose-dependent
manner in COC1/CP cells (Figure 5A). At the same time, OA also
rescued AKT phosphorylation in A2780 and OVCAR-3 cells
during ATO treatment.
To determine whether caspase-3 mediates AKT phosphoryla-
tion and the proteolysis of the A subunit linked to the increased
PP2A activity, we pre-treated cells with DEVD-CHO, a specific
caspase-3 inhibitor. The results indicated that inhibition of
caspase-3 activation restored AKT phosphorylation in the
presence of ATO at various periods of time and inhibited PP2A
proteolysis. Obvious cleavage of the A subunit, not the catalytic C
subunit; was observed at time points tested from 24 to 72 h
without DEVD-CHO (Figure 5B), suggesting that ATO-mediated
activation of PP2A may primarily be involved in the caspase-
mediated degradation of the A subunit.
To confirm the involvement of caspase-3 in PP2A activation,
PP2A activity was measured by detecting the release of phosphate
from the synthetic PP2A substrate KIpTIRR [39]. ATO
treatment caused an increase of phosphate release, indicating
elevated PP2A activity, which was blocked by pre-treating the cells
with the indicated concentration of OA or DEVD-CHO
(Figure 5C). In addition, as shown in Figure 5D, a low but
detectable quantity of the catalytic C subunit of PP2A (PP2A/C)
was co-precipitated with AKT in untreated cells, indicating the
occurrence of a physiological association between these two
proteins. Interestingly, the PP2A-AKT association was greatly
improved after a 48 h treatment of ATO, whereas this interaction
was drastically decreased by the inhibition of caspase-3 and PP2A
activation, suggesting that the dephosphorylation of AKT is a
consequence of caspase-mediated PP2A activation and that the
caspase-3-PP2A-AKT pathway is a positive feedback loop on
apoptosis. These results also indicate that BIM-caspase-AKT may
represent a new pathway which regulates ATO-induced apoptosis
in ovarian cancer cells.
The JNK pathway mediates BIM activation in cell
apoptosis
Although we have confirmed that BIM mediates AKT
activation in ATO-induced apoptosis, the mechanism of how
ATO induces BIM is obscure. Recent studies demonstrated that
ATO triggered the JNK pathway in cell apoptosis [41] and that
JNK activation modulated BIM phosphorylation and expression
[42,43]. Accordingly, we wondered if JNK is activated and
mediates BIM activation during ATO-induced apoptosis in
ovarian cancer cells. To determine the function of the JNK
pathway in BIM activation during ATO-induced apoptosis, we
analyzed the phosphorylation of JNK (p-JNK) and c-Jun (p-c-Jun).
The results demonstrated that ATO triggered the phosphorylation
of JNK and c-Jun in a time-dependent manner, suggesting that the
JNK pathway is activated during ATO-induced apoptosis
(Figure 6A). In addition, our data also revealed that JNK
activation increased BIM expression and phosphorylation, while
the JNK inhibitor SP600125 prevented BIM activation (Figure 6B).
These results suggest that the JNK pathway contributes not only to
BIM expression, but also to the phosphorylation of BIM.
To further confirm that the JNK signaling pathway mediates
BIM activation and subsequent cell apoptosis, we utilized the
dominant negative mutant of c-Jun, TAM67, which was cloned
into the pGFP-C2 plasmid. We first examined the location and
expression of GFP-TAM67 in cells. Our data showed that GFP-
TAM67 was located in the nucleus, which is consistent with results
described previously [44–46]. An immunoblotting assay also
demonstrated the expression of GFP-TAM67 in transfected cells
(Figure 6C). Previous studies demonstrated that TAM67 inhibited
the JNK pathway-mediated activation of BIM and subsequent
caspase cleavage [44,45]. Furthermore, our results revealed that
dominant-negative c-Jun not only inhibited BIM phosphorylation
and expression, but also repressed caspase activation. Therefore,
these results confirm that JNK signaling promotes BIM activation
during ATO-induced apoptosis.
Discussion
ATO, which is used effectively to treat patients with APL, not
only shows promise as a treatment for multiple cancers, but has
multiple interactions that may help overcome the cisplatin
resistance of some cancer cells [47]. Understanding the mecha-
nism by which ATO induces apoptosis may identify potential
targets for combination therapies of malignancies. In this study, we
demonstrated that ATO can induce apoptosis in ovarian cancer
cell lines, regardless of their differences in chemo-sensitivity
(Figure 1) [6]. The importance of our findings is that we identified
the precise molecular mechanisms of apoptosis in ovarian cancer
cells induced by ATO. We determined that BIM is a key mediator
during ATO-induced apoptosis by detecting the expression levels
of BCL-2-family proteins in cells. It was reported that BIM
downregulation is important for cell survival, as expression of this
death activator at levels equivalent to those induced by cytokine
withdrawal led to apoptosis, even in the presence of IL-3 [33], and
the silencing of BIM also protected cells from ATO-induced
apoptosis, indicating that upregulation of the BH3-only proteins
contributes to ATO-induced toxicity [32]. Therefore, our studies
further confirmed the important roles of BIM in ATO-induced
apoptosis, as our results demonstrate that BIM downregulation by
shRNA inhibits ATO-induced cell apoptosis.
Several labs have reported that AKT plays a role in ATO-
induced cell death [34,48]. Pre-treatment with PI-3K pathway
inhibitors enhanced ATO-induced apoptosis in leukemia cells, and
the cytotoxic effect of ATO correlated with a decrease in p-AKT,
but not total AKT [48]. In addition, the PI-3K/AKT signaling
pathway played a critical role in the carcinogenesis and drug
resistance exhibited by numerous types of cancer cells, including
ovarian cancer cells [12,13,49], supporting the importance of PI-
ovarian cells. OVCAR-3 and A2780 cells were transfected with constitutive AKT1 and were selected for 8 weeks by G-418 and treated with ATO for
72 h. Cells were lysed and assayed for individual protein levels by Western blot. Left, protein levels of p-AKT (Ser
473) and AKT (AKT1) in both Ctrl or
AKT vector transfected OVCAR-3 and A2780 cells were detected. Relative amount of protein levels were set as described in B. p-AKT and AKT levels of
AKT1 transfected A2780 cells were considered as 1. Right, analysis of apoptosis in Ctrl or AKT1 vector transfected OVCAR-3 and A2780 cells. Cell
apoptosis was quantitatively detected by a cell death ELISA kit as described in Materials and Methods. All data are depicted graphically as the means
6 standard errors of the means for at least three independent experiments. **, P,0.01. E. Detection of the role of LY294002 on apoptosis of cells.
Cells were treated with ATO and/or 25 mM LY294002 for 72 h, and then cells were lysed and assayed for individual protein levels by Western blot. Left,
protein levels of p-AKT (Ser
473) and total AKT in COC1 cells were detected. Cell apoptosis was quantitatively detected by a cell death ELISA kit.
Relative amount of protein levels were set as described in B. p-AKT and AKT levels from untreated cells were set as 1. Right, analysis of apoptotic cells
as describe in Materials and Methods. All data are depicted graphically as the means 6 standard errors of the means for at least three independent
experiments. **, P,0.01.
doi:10.1371/journal.pone.0020586.g003
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PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e20586Figure 4. BIM mediated-AKT dephosphorylation regulates apoptosis induced by ATO. A. Effect of AKT siRNA on the BIM expression. Cells
were transfected with either control siRNA or AKT1 siRNA for 48 h and then were exposed to ATO for 72 h. Cells were lysed and assayed for individual
protein levels by Western blot. CF is referred to cleaved PARP. b-Actin was used as a protein loading control. Up, protein levels of AKT, BIM, cleaved
caspase-3, and PARP were detected by Western blot. Relative amount of individual protein level was set as described in Figure 3B. p-AKT and AKT
levels of Ctrl siRNA transfected and treated A2780 cells were considered as 1. Down, analysis of apoptotic cells. as described in Material and Methods.
All data are depicted graphically as the means 6 standard errors of the means for at least three independent experiments. P.0.05 (not significant). B.
Effect of FOXO3A siRNA on the BIM expression and cell apoptosis. Cells were transfected with either control siRNA or FOXO3A siRNA for 48 h and
then were exposed to ATO for 72 h. Up, Following transfection for 48 h, Immunoblot for BIM and FOXO3A protein expression was performed on
whole cell lysates. Relative amount of individual protein level was set as described in Figure 3B. FOXO3A and BIM levels of Ctrl siRNA transfected
COC1 cells were considered as 1. Down, protein levels of BIM, cytosol cyt c and PARP were assayed by Western blot in FOXO3A siRNA OVCAR-3 cells.
For cyt c detection, cells were treated following Figure 1E. As described in Figure 3B, relative amount of BIM and cyt c in ATO treated cells (72 h)
were regarded as 1. C. Effect of AKT on BIM phosphorylation. Cells were metabolically labeled with [
32P] orthophosphoric acid and treated with ATO
(2 mM) for 48 h, and BIM was immunoprecipitated by using an agarose-conjugated BIM antibody, then detection of phosphorylation of BIM.
Phosphorylation of BIM was determined by autoradiography (upper panel). Western blot analysis was performed to confirm and quantify BIM protein
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Previous reports also demonstrated that BIM activation is
dependent on the dephosphorylation of AKT and indicated the
ability of the PI-3K inhibitor LY294002 to induce BIM expression
and apoptosis. Recent studies have suggested that the link between
reduced AKT activity and increased BIM expression levels is
FOXO3A, a member of the forkhead family of transcriptional
regulators that can directly elevate BIM expression levels and
induce apoptosis in cells. FOXO3A is phosphorylated by AKT,
leading to its cytoplasmic retention by 14-3-3 proteins and loss of
target-gene activation [24,33,50]. These findings suggest that
AKT is likely to be involved in regulating BIM expression in
ovarian cancer cells’ response to ATO stimulation.
Although our data suggested that p-AKT is necessary for
ATO-induced apoptosis, AKT downregulation by RNAi,
surprisingly, could not prevent BIM expression during ATO
treatment. Additionally, FOXO3A inhibition by RNAi had little
effect on BIM expression. Moreover, ATO treatment induced an
increase in BIM phosphorylation, even in cells transfected with
AKT RNAi. These results implied that the AKT pathway is not
involved in BIM activation. In contrast, our report suggests that
BIM activation is involved in downregulating p-AKT during
ATO-induced apoptosis. To our knowledge, the observation that
BIM can regulate the phosphorylation of AKT is a novel
finding.
In this study, we attempted to determine how BIM controls the
phosphorylation of AKT during ATO-induced ovarian cancer
cell apoptosis and which factors mediate BIM expression during
cell apoptosis. We first examined the mechanism of p-AKT, as
regulated by BIM. We observed that BIM shRNA could prevent
caspase-3 cleavage, suggesting that BIM expression is an
upstream event in caspase-3 activation. PP2A-linked, caspase-
dependent pathways were required for downregulation of AKT
kinase [34,39,40]. In this study, we also observed that AKT
phosphorylation was regulated by caspase-3-mediated PP2A
activation. Our results further confirm that BIM-mediated
AKT phosphorylation requires two stages. In the first stage,
BIM expression is regulated during ATO-induced apoptosis, and
activated BIM triggers caspase-3 cleavage and subsequent events.
In the second stage, caspase-3 activation mediates AKT
dephosphorylation, further enhancing caspase-3 activation and
ATO-induced apoptosis through a positive-feedback regulation
(Figure 7). Subsequently, we detected which factors regulate BIM
activation. A previous study suggested that ATO induces the JNK
pathway activation in apoptosis [41]. In fact, activated JNK could
modulate BIM expression and phosphorylation [42,43]. Accord-
ingly, we propose that JNK may participate in regulating BIM
expression and phosphorylation during ATO-induced ovarian
cancer cell apoptosis. Our data support the hypothesis that JNK
activation triggers BIM expression and phosphorylation in ATO-
induced apoptosis. Moreover, JNK activation was observed to be
an early response to ATO treatment and was required for
subsequent apoptotic events in cells. These result were consistent
with a recent report from Garcı ´a-Pardo’s group [51]. Their study
indicated that ATO induces JNK activation, resulting in
inhibition of the PI-3K/AKT signaling pathway in B-CLL cells
and upregulation of PTEN. However, our results did not
demonstrate PTEN upregulation during ATO-induced apoptosis.
This discrepancy regarding the process of PTEN induction
requires further research.
In this study, we explicate the molecular mechanism of ATO in
ovarian cancer cells and provide the first evidence that BIM-
mediated AKT dephosphorylation is an important factor for
ATO-induced apoptosis in cisplatin-sensitive and -resistant
ovarian cancer cells. The new JNK-BIM-AKT pathway may
explain why ATO can induce cell apoptosis in cisplatin-resistant
ovarian cancer cells (Figure 7). To understand the events involved
in ATO-induced apoptosis will require us to design combinations
of various agents with modest activities for uses as single agents in
treating tumors.
Materials and Methods
Materials
Cisplatin, arsenic trioxide, Hoechst33342, LY294002,
SP600125, DEVD-CHO and monoclonal anti-actin were ob-
tained from Sigma (St. Louis, MO). Monoclonal anti-AKT1,
polyclonal anti-AKT, polyclonal anti-phospho-AKT (Ser 473),
anti-phospho-PI-3K (Ser 85), anti-phospho-c-Jun (Ser 63), poly-
clonal anti-phospho-JNK, polyclonal anti-mTOR, polyclonal anti-
phospho-mTOR (Ser 2481 and 2448), polyclonal anti-BIM, anti-
PP2A/A, anti-PP2A/C, monoclonal anti-caspase-9 and anti-
cleaved caspase-3 were purchased from Cell Signaling (Beverly,
MA). Polyclonal anti-PTEN, anti-RICTOR, anti-PDK1, anti-
SIN1, anti-cytochrome c, anti-PARP, polyclonal anti-BAX,
PUMA, NOXA, BCL-2 and BCL-XL were obtained from Santa
Cruz (Santa Cruz, CA). The dominant-negative c-Jun plasmid
(pEGFP-TAM67) was generously provided by Dr. Jian Zhao
(Sichuan University, Chengdu, China).
Gene Silencing with Small Interfering RNAs
The small interfering RNA (siRNA) duplexes targeting the
sequence 59-UAAUGUGCCCGUCCUUGUCUU-39 of the hu-
man AKT1 gene, the sequence 59-ACUCCGGGUCCAGCUC-
CAC-39 of the FOXO3A gene and control siRNA oligonucleo-
tides were purchased from Dharmacon Research, Inc. (Lafayette,
CO). The BIM shRNA construct was a gift from Subhas C. Biswas
(Columbia University College of Physicians and Surgeons, New
York, USA) [52].
Cell Culture and Transfection
Cells were obtained from the American Type Culture
Collection (ATCC). COC1 and OVCAR-3 cells were cultured
in suspension with RPMI-1640 media (Sigma, St. Louis, MO,
USA) supplemented with 10% fetal bovine serum (FBS) (Hyclone)
and 1% penicillin-streptomycin at 37 uC under 5% CO2. A2780
cells were incubated in DMEM media supplemented with 10%
FBS and 1% penicillin-streptomycin. Cisplatin-resistant cells were
obtained by reiterating treatments with increasing concentrations
of cisplatin. These cell lines were grown as described previously
(lower panel). Left, the effect of LY294002 on BIM phosphorylation. Cells were treated with ATO and/or LY294002 (25 mM), then detection of BIM
expression and phosphorylation. As described in Figure 3B, relative amount of
32p-BIM and BIM in ATO treated cells were regarded as 1. Right, the
effect of AKT siRNA on BIM phosphorylation. Cells were transfected with either control siRNA or AKT1 siRNA for 48 h and then were exposed to ATO
for 48 h. Detection of BIM expression and phosphorylation as described. Relative amount of
32p-BIM and BIM in AKT transfected and ATO treated cells
were set as 1. D. Effect of BIM shRNA on AKT phosphorylation. Cells were transfected with either control shRNA or BIM shRNA for 48 h and then were
exposed to ATO for 48 h. Western blot examined BIM expression, caspase-3 cleavage, protein levels of p-AKT (Ser
473) and AKT in cells. Relative
amount of p-AKT, AKT and BIM in Ctrl shRNA transfected and ATO treated cells were set as 1. All data are representative of three independent
experiments.
doi:10.1371/journal.pone.0020586.g004
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PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e20586Figure 5. Caspase-3 mediates PP2A-related AKT dephosphorylation. A. Different cells were pre-incubated with indicated concentrations of
OA for 1 h and exposed to ATO for 48 h, then lysed in NP40 buffer for detection. Western blot analysis of total AKT and p-AKT (Ser
473) levels was
shown. b-Actin was used as a protein loading control. Relative amount of p-AKT and AKT in untreated cells were set as 1. B. Analysis of the effect of
caspase-3 on PP2A activation. Up, Cells were pre-incubated with indicated concentrations of DEVD-CHO for 1 h and exposed to ATO for 48 h, then
lysed in NP40 buffer for detection. Western blot analysis of total AKT and p-AKT (Ser
473) levels was shown. Relative amount of p-AKT and AKT in
untreated cells were set as 1. Middle, the treated cells were lysed with sample buffer and subjected to immunoblot assay with an A subunit-specific
anti-PP2A/A antibody. CF is referred to cleaved PP2A/A. The membrane was then stripped and reprobed with a C subunit-specific anti-PP2A/C
antibody. Relative amount of PP2A/C in untreated cells (0 h) were set as 1. Down, Western blot analysis of the effect of DEVD-CHO (100 mM) in PP2A
cleavage. C. Detection of PP2A activity. Cells were pre-incubated with or without 0.2 mM of OA or 100 mM of DEVD-CHO for 1 h and exposed to drug
for 48 h. PP2A activity with the cellular proteins extracted from RIPA buffer-lysed cells was measured using phosphopeptide KIpTIRR as a substrate as
described in Materials and Methods. Each column represents the mean 6 S.D. of triplicate assays. *, P,0.05. D. Detection of the binding of AKT with
PP2A. Cells were incubated with or without ATO for 48 h. In some groups of cells, 0.2 mM of OA or 100 mM of DEVD-CHO was added 1 h prior to the
addition of drug. The cells were then lysed with RIPA buffer for immunoprecipitation with anti-AKT antibody followed by immunoblot assay with anti-
PP2A/C and anti-AKT antibodies. Relative amount of individual protein in untreated cells were set as 1. Data are representative of at least three
independent experiments.
doi:10.1371/journal.pone.0020586.g005
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exposing the cells to 5 mg/ml cisplatin under the same conditions
as described above. Despite massive cell death concurrent with
treatment, the cultures were maintained for four to six weeks by
regular changes of culture medium until the drug-surviving cells
recovered a normal growth pattern. Next, cisplatin treatment was
reiterated with elevated concentrations (7.5-10 mg/ml). After
establishment, the chemo-resistant variants were treated with
cisplatin every month to maintain their high level of chemo-
resistance.
For transfection, cells were placed on 6-well plates and
transfected with the appropriate plasmid DNA or siRNA using
the protocol described by the manufacturer. Typically, 1 mgo f
plasmid DNA or siRNA and 4 ml of DMRIE-C reagent
(Invitrogen) were used per coverslip. The cells were incubated
for 4 h in the transfection mixture, which was then replaced with
fresh culture medium. Positive clones were selected with 1 mg/ml
G418 for several weeks. For overexpression of AKT, cells were
transfected with the constitutively active AKT1 construct HA-
PKB-T308D/S473D as previously described [24].
Cell Viability and Apoptosis Assay
Ovarian-cell viability was assessed by the 3-(4,5-dimethylthia-
zol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay as
Figure 6. JNK pathway upregulates BIM expression and phosphorylation. A. Detection of p-JNK, and p-c-Jun in cells. COC1 cells were
treated with ATO (2 mM) for different periods of time, then lysed with sample buffer and subjected to immunoblot assay with antibodies for
phosphor-c-Jun (Ser 63) or polyclonal-phospho-JNK. COC1/CP cells were treatd with ATO for 72 h, then lysed for detection. Relative amount of p-JNK
and p-c-Jun in untreated cells (72 h) were set as 1. B. JNK inhibitor prevents BIM expression and phosphorylation. Cells were treated with ATO (2 mM)
for 72 h in the presence of JNK inhibitors SP600125 (10 mM). Lysated cells were immunoblotted with antibodies for phospho-c-Jun (Ser 63),
polyclonal-phospho-JNK, phospho-AKT (Ser 473) or polyclonal-BIM. BIM phosphorylation was detected as described in Figure 4. Relative amount of
p-JNK, p-c-Jun,
32p-BIM and BIM in ATO treated cells were set as 1. Relative fold means amount of p-AKT from untreated cells were regarded as 1. C.
Dominant negative c-Jun inhibits BIM expression and phosphorylation. Left, OVCAR-3 cells were transiently transfected with pEGFP-TAM67 mutant or
control vector (Ctrl vector). The mutant location was detected by microscopy. Middle, COC1/CP cells were transfected with pEGFP-C2 or pEGFP-
TAM67, then lysed with antibodies for GFP or c-Jun. lane 1: cells with pEGFP-C2 vector. 2: untransfected cells. 3: cells with pEGFP-TAM67. Relative fold
means amount of GFP in pEGFP-C2 vector transfected cells was regarded as 1. Right, A2780 cells were transfected with pEGFP-TAM67 or Ctrl vector.
Stable positive clones were selected with 1 mg/ml G418 for several weeks. Ctrl vector transfected cells were treated with ATO (2 mM) and/or
SP600125 for 72 h. pEGFP-TAM67 transfected cells were also incubated with ATO for 72 h. Lysated cells were immunoblotted with antibodies. BIM
phosphorylation was detected as described in Figure 4. In all immunoblot analysis, b-Actin was used as a protein loading control. Relative amount of
32p-BIM and BIM in ATO treated cells were set as 1. All data are representative of three independent experiments.
doi:10.1371/journal.pone.0020586.g006
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assess drug-induced apoptotic cell death: detection of DNA
fragmentation with the Cell Death Detection ELISA kit (Roche
Diagnostics); western blot analysis for caspase activation and
PARP cleavage; nuclear staining with Hoechst 33342;Annexin V
analysis by flow cytometry. The cell death detection ELISA was
performed to quantify the apoptotic index by detecting the
histone-associated DNA fragments (mono- and oligo-nucleosomes)
generated by the apoptotic cells [24]. In brief, the ovarian cells
were treated with agents and were collected to prepare the cytosol
fractions that contained the smaller fragments of DNA. Equal
volumes of these cytosolic fractions were incubated in anti-histone
antibody-coated wells (96-well plates), and the histones of the DNA
fragments were allowed to bind to the anti-histone antibodies. The
peroxidase-labeled mouse monoclonal DNA antibodies were used
to localize and detect the bound fragmented DNA using
photometric detection with 2, 29-azino-di-(3-ethylbenzathiazoline
sulfonate) as the substrate, according to the manufacturer’s
instructions.
Cell Fractionation
Cells were fractionated by differential centrifugation as
previously described [54]. Briefly, cells were harvested and
resuspended in three volumes of hypotonic buffer (210 mM
sucrose, 70 mM mannitol, 10 mM Hepes, pH 7.4, 1 mM EDTA)
containing 1 mM phenylmethylsulfonyl fluoride, 50 mg/ml tryp-
sin inhibitor, 10 mg/ml leupeptin, 5 mg/ml aprotinin, and
10 mg/ml pepstatin. After gentle homogenization with a Dounce
homogenizer, the cell lysates were centrifuged at 1,0006g for
5 min to remove unbroken cells and nuclei. The supernatant was
collected and centrifuged at 10,0006g to pellet the mitochondria-
enriched heavy membrane fraction. The supernatant was further
centrifuged at 100,0006g to obtain a cytosolic fraction.
SDS-PAGE and Immunoblotting
SDS-PAGE and immunoblotting were performed as described
elsewhere [54]. Briefly, the cells or the membrane fractions were
resuspended in a lysis buffer containing Nonidet P-40 (10 mM
Hepes, pH 7.4, 2 mM EGTA, 0.5% Nonidet P-40, 1 mM NaF,
1 mM NaVO4, 1 mM phenylmethylsulfonyl fluoride, 1 mM
dithiothreitol, 50 mg/ml trypsin inhibitor, 10 mg/ml aprotinin,
and leupeptin) and were placed on ice for 30 min. The lysates
were centrifuged at 12,0006g for 12 min at 4 uC, and the protein
concentration was measured. Equivalent samples (30 mgo f
protein) were subjected to SDS-PAGE on 12% gels. The proteins
were then transferred onto nitrocellulose membranes and probed
with the indicated antibodies followed by the appropriate
secondary antibodies conjugated to horseradish peroxidase
(KPL, Gaithersburg, MD). Immunoreactive bands were visualized
using enhanced chemiluminescence (Pierce). The molecular sizes
of the proteins detected were determined by comparison with
prestained protein markers (Invitrogen).
Phospho-Amino Acid Analysis
Ovarian cancer cells were metabolically labeled with [
32P]
orthophosphoric acid for 120 min and treated with ATO for 48 h.
32P-Labeled BIM was immunoprecipitated using an agarose-
conjugated BIM antibody, separated by SDS-PAGE and trans-
ferred to a polyvinylidene difluoride membrane. The membrane
slice containing BIM was excised and hydrolyzed in 5.7 N HCL
(Pierce) at 110 uC for 90 min under a vacuum. Cold phospho-
serine, phosphothreonine and phosphotyrosine were added to the
sample. Next, they were applied together onto a TLC plate and
separated by electrophoresis utilizing a Multiphor II apparatus
(Amersham Biosciences) with an equal volume of pH 1.9 and
pH 3.5 buffers as described previously [55]. The location of
phospho-amino acids was determined by ninhydrin staining and
autoradiography.
Determination of PP2A activity
A nonradioactive, malachite green-based serine/threonine
phosphatase assay kit (Upstate Biotechnology, Lake Placid, NY,
USA) was used to measure phosphatase activity [39]. Briefly,
5 mg of cellular proteins extracted in lysis buffer were incubated
with 175 mM of the phosphopeptide (KIpTIRR) and the PP2A
buffer (20 mM MOPS, pH7.5, 60 mM 2-ME, 0.1 M NaCl and
0.1 mg/ml serum albumin) in a total volume of 25 ml. Reactions
were started by the addition of the phosphopeptide substrate and
conducted for 10 min at room temperature. The reactions were
terminated by the addition of malachite green solution, and the
solution was left for 15 min to allow color development. Next, the
plate was read at 650 nm with a microplate reader, and the
amount of released phosphate was calculated from a standard
curve. Although the reaction buffer and phosphorylated substrate
in this assay were designed to detect PP2A, this assay may not
fully discriminate between PP2A and PP1. Therefore, the
sensitivity of the measured phosphatase activity to 0.2 mM
Figure 7. A diagram of signaling pathway for ATO-mediated
BIM activation and apoptosis in ovarian caner cells. ATO
induced JNK pathway activation, and then activated JNK regulated
BIM activation. BIM expression upregulated caspase-3 activation and
subsequent apoptosis at the first stage. Activated caspase-3 triggered
PP2A-linked AKT dephosphorylation, and then AKT dephosphorylation
further enhanced caspase-3 cleavage and apoptosis at the second
stage.
doi:10.1371/journal.pone.0020586.g007
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determined for the assay.
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